

Kristine Kleivi Sahlberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5880083/kristine-kleivi-sahlberg-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

608
citations

11
h-index

21
g-index

21
ext. papers

801
ext. citations

8.9
avg, IF

3.45
L-index

#	Paper	IF	Citations
19	Abstract OT2-19-01: Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study. <i>Cancer Research</i> , 2022 , 82, OT2-19-01-OT2-19-01	10.1	
18	miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.. <i>Breast Cancer: Targets and Therapy</i> , 2022 , 14, 25-39	3.9	1
17	MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro. <i>Scientific Reports</i> , 2021 , 11, 10893	4.9	4
16	Radiological review of prior screening mammograms of screen-detected breast cancer. <i>European Radiology</i> , 2021 , 31, 2568-2579	8	3
15	miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer. <i>PLoS Computational Biology</i> , 2021 , 17, e1008608 ⁵		0
14	Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway. <i>Radiology</i> , 2020 , 294, 256-264	20.5	26
13	Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. <i>Oncotmmunology</i> , 2020 , 9, 1824644	7.2	3
12	miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. <i>Molecular Oncology</i> , 2019 , 13, 2278-2296	7.9	19
11	An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. <i>Nature Communications</i> , 2019 , 10, 5499	17.4	55
10	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. <i>Breast Cancer: Targets and Therapy</i> , 2017 , 9, 185-198	3.9	17
9	DNA methylation at enhancers identifies distinct breast cancer lineages. <i>Nature Communications</i> , 2017 , 8, 1379	17.4	71
8	A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. <i>Thrombosis Research</i> , 2017 , 157, 111-116	8.2	17
7	Determinants of acquired activated protein C resistance and D-dimer in breast cancer. <i>Thrombosis Research</i> , 2016 , 145, 78-83	8.2	7
6	A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. <i>Clinical Cancer Research</i> , 2015 , 21, 1207-14	12.9	156
5	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. <i>Genome Medicine</i> , 2015 , 7, 21	14.4	24
4	Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. <i>Breast Cancer Research</i> , 2015 , 17, 44	8.3	16
3	High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. <i>Molecular Oncology</i> , 2014 , 8, 93-104	7.9	127

- | | | |
|---|---|--------|
| 2 | The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description. <i>Genomics Data</i> , 2014 , 2, 249-53 | 6 |
| 1 | The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. <i>Molecular Oncology</i> , 2013 , 7, 392-401 | 7-9 56 |